Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...